Could Eli Lilly & Co.'s CDK 4/6 inhibitor abemaciclib beat Novartis AG's offering to market and trespass on Pfizer Inc.'s Ibrance (palbociclib) sales more than a year earlier than anticipated?
In its fourth quarter earnings call, Lilly surprised investors by suggesting it would consider filing abemaciclib as a treatment for...


![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

